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Abstract
The right and left hearts differ from one another in their anatomy and function. This disparity demonstrates itself in 
different heart muscle compositions, arrangements of cardiac conduction system elements, and distributions of auto-
nomic nervous system receptors. These differences mean that diseases that mainly affect the right heart, such as acute 
pulmonary embolism, chronic pulmonary hypertension, right ventricular infarction or arrhythmogenic right ventricular 
cardiomyopathy, as well as some congenital heart diseases and connective tissue diseases, have a distinct clinical 
course and potential complications. This leads to an increased incidence of cardiac rhythm disturbances in this group, 
with distinctive types of arrhythmia specific for every disease. In order to help clinicians select the best diagnostic and 
therapeutic methods, we here summarise current knowledge about arrhythmic complications and cardiac autonomic 
nervous system functions in diseases with right heart involvement.
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Introduction
The right and left ventricles differ in their anatomy and 
function, which is reflected in the different structure of 
the myocardium, different composition of the conductive 
system, and different distribution of autonomic nervous 
system receptors. Taking into account the wide spectrum of 
acute and chronic diseases mainly involving the right ven-
tricle, the following review summarises current knowledge 
about cardiac arrhythmias and the function of the autono-
mic nervous system in diseases such as acute pulmonary 
embolism (APE), chronic pulmonary hypertension (PH), right 
ventricular infarction (RVI), arrhythmogenic right ventricular 
cardiomyopathy (ARVC), as well as congenital heart defects 
and connective tissue diseases with dominant right ven-
tricular involvement.
In clinical practice we have several non-invasive or 
minimally invasive methods to assess the functions of the 
autonomic nervous system, of which the most commonly 
used are: assessment of heart rate variability (HRV), mea-
surement of heart rate turbulence (HRT), assessment of 
arterial baroreceptor activity, and the orthostatic or tilt test. 
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A detailed discussion of these methods and their impor-
tance in everyday practice, especially in predicting the risk 
of arrhythmic events, is available in medical publications 
[1, 2]. Today there is no doubt about the importance of 
inadequately increased sympathetic activity in promoting 
the occurrence of arrhythmia. Although the assessment 
of autonomic system function has traditionally been used 
mainly in patients after myocardial infarction or chronic 
heart failure with impaired left ventricular systolic function 
(especially by using HRV and HRT) [1, 2], there is more and 
more data regarding their potential use in diseases with 
dominant right ventricular involvement, as discussed in 
the following article.
Acute pulmonary embolism
Venous thromboembolism (VTE) is the third most com-
mon cardiovascular disease. Its most dangerous clinical 
manifestation is APE, the main cause of hospitalisation, 
morbidity and mortality in Europe. In the management 
of a patient with newly diagnosed APE, all too often not 
enough attention is given to the potential occurrence of 
various arrhythmias and their prognostic significance, 
and even more rarely to the possible dysregulation of the 
autonomic system resulting in abnormal cardiovascular 
reactions. However, the clinical course of APE with acute 
right heart pressure overload is often complicated by car-
diac arrhythmias. Arrhythmia may additionally be favoured 
by myocardial ischaemia and blood hypoxemia [3].
Supraventricular arrhythmias
A significantly increased risk of atrial fibrillation (AF) in 
the course of APE has been demonstrated by Australian 
researchers. The incidence of AF in a group of 1,142 pa-
tients with APE was as much as 13%, and the risk of this 
arrhythmia was more than nine times higher compared 
to the age-adjusted general population. Moreover, it was 
shown that patients with APE and atrial fibrillation had more 
comorbidities. Independent risk factors for this arrhythmia 
included age (p < 0.001), history of congestive heart fai-
lure (p = 0.02), diabetes (p = 0.02), and obstructive sleep 
apnoea (p = 0.009) [4].
The occurrence of atrial fibrillation (de novo, persis-
tent or chronic) in the course of APE may also result in 
a non-optimal initial assessment during the diagnostic 
process when this disease is suspected. Although the 
reported frequency of tachycardia on the first day in APE 
is 24–39%, no detailed data is available on the incidence 
of atrial fibrillation in these statistics [3]. One study 
indicated that patients with supraventricular tachyar-
rhythmias are more often assigned to the high probability 
group of venous thromboembolism based on a modified 
Geneva scale (p = 0.04), and this group also scored higher 
on the simplified Pulmonary Embolism Severity Index 
(sPESI) scale (p < 0.001), which could be attributed to 
scoring additional points for tachycardia > 110/min. [5]. 
Another noteworthy observation arising from this study is 
the fact that in patients with paroxysmal AF (compared 
to patients with sustained arrhythmia or sinus rhythm), 
indirect echocardiographic features of right ventricular 
congestion were observed more frequently, i.e. increased 
calculated pressure in the pulmonary trunk (p = 0.01) or 
reduced acceleration time through the pulmonary valve 
(p = 0.04). However, in this study no significant relation-
ship was found between atrial fibrillation and in-hospital 
mortality (p = 0.067), and therefore the question re-
garding the impact of this arrhythmia on the risk of APE 
patients’ death remains unresolved [5].
The relationship between APE and the occurrence of 
supraventricular arrhythmia is also highlighted by the analy-
sis of Hayiroğlu et al. [6], which describes the relationship 
between the occurrence of specific arrhythmias depending 
on thrombolytic therapy usage or the lack of it. In this study, 
using non-invasive treatment resulted in significantly more 
frequent different atrial arrhythmias (p < 0.001), despite 
the lack of clear differences in the structure and volume 
of the atria between the assessed groups [6]. The further 
analysis of the obtained results is ambiguous, because 
patients who required thrombolytic treatment had worse 
clinical status at the baseline (and supraventricular ar-
rhythmias presented less often). In addition, no differences 
in the incidence of ventricular arrhythmias were observed 
between the assessed groups. On the other hand, the 
dissolving of thrombi during fibrinolytic therapy not only 
improves cardiovascular and respiratory function, but also 
reduces the thrombus load and, consequently, the release 
of proinflammatory cytokines from them, which are also 
seen as potential factors that increase the occurrence of 
various arrhythmias [6].
Ventricular arrhythmias
Currently, there is no detailed data on the occurrence, 
clinical course or implications of ventricular arrhythmias 
in the course of APE.
Prognostic value
It is worth noting that the occurrence or severity of cardiac 
arrhythmias [as well as other electrocardiographic (ECG) 
abnormalities] may also be the first manifestation of the 
onset of clinical worsening in the course of APE: unexpla-
ined bradycardia, seemingly inadequate tachycardia with 
episodes of tachyarrhythmia, as well as the occurrence of 
intraventricular conduction disorders indicate a developing 
shock, most commonly just after a progressive reduction of 
blood pressure. The significance of specific abnormalities 
in standard 12-lead ECGs indicating adverse in-hospital 
and long-term prognosis in patients with APE have been 
discussed in detail in other studies [7].
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Syncope and its association  
with cardiac arrhythmias
According to data from various studies, fainting and synco-
pe in patients with APE are observed in up to 10% of cases, 
and adverse effects of these events on the prognosis have 
been proven [8]. It seems that the fainting and syncope 
are usually reflexive, but it cannot be excluded that short-
-term haemodynamic instability is the result of brady- or 
tachyarrhythmia. It has been shown that syncope in the 
course of APE is more common in people with pre-existing 
left bundle branch block (LBBB) and in patients with fresh 
right bundle branch block (RBBB) (high probability of short-
-term bradyarrhythmia) [9].
Autonomic heart system
The risk of bradyarrhythmia in the course of APE, overlooked 
in risk stratification, is also partly justified in the aspect 
of the autonomic regulation of the cardiovascular system 
disorders in the course of APE. In healthy pulmonary arte-
ries, the vascular tone is low, which means that at rest they 
are maximally expanded. The pulmonary circulation vessels 
are equipped with noradrenergic receptors with variable 
densities depending on the dimensions of individual arter-
ioles, and are not present in vessels < 700 μm in diameter. 
Stimulation of the sympathetic nervous system has been 
found to have a different effect depending on whether the 
pulmonary arteries have normal or elevated pressure. In 
the course of acute pulmonary hypertension (PH), adrena-
line has a vasodilating effect on vessels equipped with 
receptors that capture it, and this vasodilatory effect, in 
addition to vasoconstriction, is caused by noradrenaline 
and epinephrine. Ultimately, activation of the sympathetic 
nervous system under PH conditions results in vasocon-
striction followed by vasodilation. In addition, sympathetic 
stimulation increases the tone of the pulmonary venous 
system, which further increases the pressure in the arte-
rial system and intensifies the mechanisms discussed 
above [10]. It has been observed that the severity of the 
sympathetic nervous system activity, as well as the renin– 
–angiotensin–aldosterone axis, is also affected by the load 
and distribution of thrombi and the duration of vascular 
occlusion. It is also suspected that in neurohormonal 
disorders Bezold-Jarish reflexes play an important  role, 
and the apnoeas, bradycardia and hypotension caused in 
their course may additionally contribute to the complicated 
clinical course [10].
There is no doubt, therefore, that in patients with APE, 
the severity of autonomic disorders may have a significant 
impact on the course of the disease, including the occur-
rence of specific arrhythmias or the occurrence of fainting 
and syncope. It is therefore surprising that there have been 
no studies that would non-invasively assess the function 
of the autonomic heart system in patients with APE, for 
example using HRV or HRT.
Treatment
It should also be remembered that due to a lack of specific 
recommendations for the treatment of cardiac arrhythmias 
complicating APE, antiarrhythmic regimens appropriate for 
the general population are used, and that causative therapy 
is of paramount importance in such a situation [3].
Pulmonary hypertension
Pulmonary hypertension is diagnosed if the mean pulmo-
nary artery pressure is ≥ 25 mm Hg when measured by 
direct invasive methods during right heart catheterisation 
[11]. Pulmonary hypertension can be a primary disease, 
or secondary to other diseases including pulmonary throm-
boembolism after APE (so-called chronic thromboembolic 
PH). Chronic PH is associated with progressive heart fail-
ure, and as a consequence autonomic dysfunction which 
could cause dysregulation of beta-adrenergic receptors in 
the myocardium, among others. Complex mechanisms of 
organic damage and functional dysfunction, typical of heart 
failure, may result in various cardiac arrhythmias in these 
patients. As in the case of acute PH in APE, issues related 
to arrhythmias in patients with chronic PH are insufficiently 
understood among practitioners.
Supraventricular arrhythmias
The results of available studies indicate that various types 
of supraventricular arrhythmias are observed relatively 
frequently in the course of PH. In one study, conducted 
on a population of 231 people with arterial PH, the cu-
mulative risk of significant arrhythmias was 11.7%, and 
the annual risk was 2.8% per patient. The presence of 
arrhythmias was associated with a worse prognosis. In 
the population assessed in this study, the most common 
arrhythmias were atrial flutter (AFL) (in 6.5%), atrial fi-
brillation (AF) (in 5.6%), and recurrent tachycardia in the 
atrioventricular (AV) node (in 1.3%) [12]. Significantly, in 
people with PH and AF, deaths were much more frequent 
(in up to 82% of cases!) when compared to patients in 
whom sinus rhythm was restored (in 6.3% of cases) [12]. 
Olsson et al. [13] found at least one de novo AFL or AF 
episode in 25% of people in another study conducted 
prospectively over five years on a group of 239 PH pa-
tients. In addition, both supraventricular arrhythmias 
occurred at a similar frequency, and their presence was 
associated with a significant worsening of the clinical 
condition (in 80%) and worsening of heart failure (in 
30% of patients). In addition, it was demonstrated that 
unmeasured AF resulted in a significant increase in the 
risk of death in this group (p = 0.01) [13]. In a systematic 
review, Handoko et al. [14] reported a significantly lower 
incidence of supraventricular arrhythmias in patients 
with PH, i.e. about 3% per year, confirming the adverse 
prognostic value of persistent atrial fibrillation.
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from cardiovascular causes associated with an increase in 
the number of late ventricular potentials in the group of pa-
tients with arterial PH compared to those with heart failure 
in the course of left ventricular dysfunction (p = 0.024). 
In both groups, the WHO functional class distribution was 
similar, and no statistical differences were found for most of 
the assessed HRV parameters. The prognostic implications 
of these irregularities require further observation [19].
Right ventricular heart failure
As mentioned earlier, the onset or worsening of cardiac 
arrhythmias in PH patients actually accelerates the onset 
of heart failure [20]. Atrial fibrillation is the most common 
arrhythmia in the group with right ventricular heart failure 
(RVHF). It is estimated that it occurs in up to 50% of pa-
tients, with an increasing frequency depending on a larger 
functional class [20]. Ventricular arrhythmias are also com-
mon, especially in those who also have a left ventricular 
ejection fraction. Myocardial damage and increased fibrosis 
provide the substrate for reentry loops, and this mechanism 
is considered to be responsible for most malignant and 
potentially malignant ventricular arrhythmias.
Treatment
The treatment of supraventricular arrhythmias in chronic 
PH does not differ significantly from the treatment of car-
diac arrhythmias in other clinical situations. For AF, AFL 
and tachycardia, electrical cardioversion and ablation of 
arrhythmia are used. Pharmacotherapy includes the use 
of beta-blockers, non-dihydropyridine calcium antagonists, 
digoxin and amiodarone [12]. The negative inotropic effect 
of the first two of these drug groups may be undesirable 
in patients with high right ventricular afterload, therefore 
their use must be preceded by a risk and benefit evaluation 
and they must undergo regular clinical monitoring. It is 
worth remembering that the use of amiodarone in patients 
with primary PH is associated with a much more frequent 
occurrence of thyroid dysfunction compared to the general 
population (19–24% vs. 2.5–9.5%) [21]. Amiodarone may 
also have side effects affecting the respiratory system, 
which includes the development of pulmonary fibrosis, and 
thus a further increase in pulmonary artery pressure [22].
Right ventricle infarct
Right ventricular infarction usually coexists with acute 
myocardial infarction with ST-segment elevation of the left 
ventricular wall, which occurs in 30–50% of cases. The term 
‘right ventricular infarction’ is, in fact, an imprecise term 
because, in addition to conditions with typical necrosis, in 
some cases, acute ischaemic right ventricular dysfunction 
resulting in a diagnosis or RVI is mostly related to a viable 
myocardium [23, 24].
Ventricular arrhythmias
The available data on ventricular arrhythmias in chronic 
PH is very limited. Although the review by Handoko et al. 
[14] cited above reports the estimated risk of death from 
ventricular arrhythmias in patients with PH to be 8–26%, 
a full assessment of the incidence and impact of ventricular 
arrhythmias on the clinical course and prognosis in patients 
with PH requires further studies.
In one of the few studies, Witte et al. [15] among a group 
of 64 participants with PH found more than twice as many 
extrasystoles compared to the control group (p < 0.01), as 
well as observed an increased risk of malignant ventricular 
arrhythmias in this population. In our Holter assessment of 
22 patients with arterial and 11 patients with thromboem-
bolic PH, we found non-sustained ventricular tachycardia 
occurrence in these patients to be 13.6% and 27.3%, 
respectively (p = 0.63) [16].
Autonomic heart system
More and more data indicates a significant dysregula-
tion of the cardiac autonomic system in people with PH, 
regardless of its cause and regardless of the age of the 
patient [17]. These patients show significantly worse HRV 
and HRT parameters, indicating chronic overstimulation 
of the sympathetic nervous system. Study from our centre 
has also shown that people with PH and abnormal HRT 
are characterised by a significant deterioration of various 
functional, biochemical and haemodynamic parameters, 
such as: 6-minute walk test distance (p = 0.05), resting 
saturation (p = 0.05), post-exercise desaturation (p = 0.03), 
or N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
concentration (p = 0.02) [18]. These results indicate that 
there is a clear relationship between the stage of PH and 
the function of the autonomic system. This means that 
the easily interpretable HRT result is potentially useful in 
predicting the increased risk of clinical deterioration, and 
possibly also death. Interestingly, during the continuation 
of previous research in our centre, it was shown that the 
severity of Holter dysfunction assessed by the Holter 
method is potentially greater in the case of thromboem-
bolic aetiology than arterial PH and in more advanced 
clinical forms [World Health Organisation (WHO) classes 
3 and 4 vs. 1 and 2] [16]. The results published by Witte 
et al. [15] stand in opposition to the above observations, 
which confirmed a decrease of HRV in arterial PH, but not 
in the case of thromboembolism. A potential explanation 
for the differences observed between the studies is a dif-
ferent selection of study groups. Given the current state 
of knowledge, possible differences in the functions of the 
autonomic system and their importance in the course of 
arterial and thromboembolic PH require further evaluation.
An interesting comparative analysis was also carried 
out in the Łódź centre, observing a greater risk of death 
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Prognostic value
An assessment in the early 1990s showed that RVI was an 
independent factor in the development of serious compli-
cations, including cardiogenic shock, ventricular fibrillation, 
third-degree AV, and the need for temporary stimulation. 
Moreover, the right ventricular infarction resulted in incre-
ased in-hospital mortality, from 5% to 31% (p < 0.001), and 
an increased serious complication rate, from 28% to 64% 
(p < 0.001) [25]. In addition to the increased risk of early 
peri-infarct complications, RVI also results in an increased 
risk of long-term mortality. The group most affected by 
unfavorable prognosis comprises patients with RVI without 
improvement of right ventricular haemodynamic function 
and with accompanying PH, as demonstrated during an 
eight-year follow-up by Shahar et al. [26].
Bradyarrhythmias
In a recently published study by Kumar et al. [24], co-
existing RVI was found in 32.9% of 573 patients from 
an Indian population with an inferior heart wall infarc-
tion treated with thrombolysis. Importantly, cardiogenic 
shock (22.2 vs. 1.8%) and death (14.3 vs. 2.34%) were 
significantly more frequent in the subgroup of pa-
tients with RVI. Patients with concomitant RVI also had 
a higher incidence of total AV block (30.2 vs. 16.4%), 
while second-degree AV block (4.8 vs. 11.7%) was less 
frequently observed. The presence of AV blocks (espe-
cially total) also resulted in a significantly more frequent 
occurrence of peri-infarction deaths (p < 0.03) [24]. The 
latest data suggests that in highly developed countries, 
where percutaneous coronary intervention is commonly 
used in the treatment of acute coronary syndromes, 
the incidence of clinically significant AV blocks has 
decreased to approximately 3% and usually resolves 
spontaneously within 2–7 days. AV blocks of a longer 
duration may require prolonged, or even permanent, 
cardiac electrostimulation, and this occurs in approxi-
mately 9% of cases. Patients with myocardial infarction 
irrespective of its location complicated by AV block are 
at higher risk of in-hospital death and over the course of 
a 30-day follow-up. However, the presence of AV conduc-
tion disorders does not affect the long-term prognosis, 
defined as death within > 30 days post-myocardial in-
farction. Indications for permanent AV stimulation are 
persisting total AV block (especially in co-existence of 
RVI), and haemodynamic instability [27].
Patients with prolonged ischaemia and long-term chest 
pain, in whom coronary revascularisation was incomplete, 
as well as patients with pre-existing arrhythmia substrate, 
bear the highest risk of potentially serious arrhythmias 
during myocardial infarction [28]. It is worth remembering 
that most arrhythmias appear in the first hours of myocar-
dial infarction and disappear after successful invasive 
treatment, and so reperfusion therapy should be sought 
as soon as possible.
Sinus bradycardia
A common complication in the course of RVI is sinus bra-
dycardia, which usually does not require special treatment 
(although atropine should be used if it causes hypotension). 
It has been proved that the presence of sinus bradycardia 
(without AV block) and hypotension increase the risk of 
cardiodepressive reflex activations from the cardiac vagus 
branches located in the inferior wall and right ventricle 
(Bezold-Jarish reflexes) [29]. Furthermore, it has been 
found that acute myocardial infarction induces morphologi-
cal and phenotypic changes in the intracardiac components 
of the autonomic system, incorrectly reducing the neuron’s 
potential in response to specific stimuli [30].
Autonomic system
There is an extensive evidence that in patients with acute 
myocardial infarction, excessive activity of the sympathetic 
nervous system results in an increased risk of cardiova-
scular events, including sudden cardiac deaths caused by 
arrhythmia. The protective effect of the parasympathetic 
nervous system in these patients has also been demon-
strated. In recent years, a great number of studies have 
been conducted involving large groups of patients that have 
proven the influence of the autonomic heart system on pro-
gnosis after myocardial infarction. Most often, non-invasive 
measurement of heart rate variability and turbulence is 
used to assess the function of the parasympathetic balan-
ce (reduced HRV and HRT parameters indicate increased 
risk) [31]. To date however, no extensive and significance-
-oriented studies focused on imbalances in the autonomic 
system have been conducted to assess the course and 
prognosis of patients with concomitant RVI.
Treatment
Treatment of cardiac arrhythmias in RVI does not deviate 
from the standard management of peri-infarct arrhythmias. 
Detailed procedures are included in the current guidelines 
of scientific societies, including the European Society of 
Cardiology.
Arrhythmogenic right  
ventricular cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is 
a congenital heart disease with autosomal dominant inheri-
tance due to mutations in the genes encoding desmosomes 
or desmosome-associated proteins. In the course of ARVC, 
myocardial fibrous fat remodelling occurs, which is clinically 
manifested by the occurrence of cardiac arrhythmias (most 
often ventricular) and progressive impairment of the right 
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systolic function, and in some patients also the left ventricle 
[32]. Despite non-sex-chromosomal inheritance, clinical 
manifestations of ARVC are three times more common in 
men than in women. In addition, men are more likely to 
present symptomatic arrhythmias (p < 0.01). What is more, 
arrhythmias in males appear earlier and are more severe 
than those suffered by women [33, 34].
There are three phases of ARVC progression: 1) asymp-
tomatic, during which patients do not experience symptoms 
of the disease, but may develop ventricular arrhythmias and 
sudden cardiac deaths; 2) the phase of electrical dysfun-
ction of the heart, manifesting as symptomatic arrhythmias 
and morphological abnormalities within the right ventricle, 
not detected using traditional imaging methods; 3) end-
-stage, characterised by signs of heart failure and frequent 
ventricular arrhythmias in the form of unstable or sustained 
ventricular tachycardia. Regardless of the severity of ARVC, 
the possibility of sudden cardiac arrest in the course of this 
disease should be considered.
Fibrous-fat tissue replacing normal myocardium in 
patients with ARVC causes a delay in right ventricular 
activation. These changes are first observed within the 
free wall and outflow tract from the right ventricle, which 
promotes the formation of re-entry loops and contributes to 
the formation of ventricular arrhythmias with the morpho-
logy of the LBBB [35]. Ventricular tachycardias with typical 
morphology from the right ventricular outflow tract occur 
much less frequently in the course of ARVC [32].
Risk of ventricular arrhythmia
In their meta-analysis, Bosman et al. [36] observed that 
the main predictor of ventricular arrhythmias in this pa-
tient group is right ventricular dysfunction. The frequency 
of ventricular arrhythmias they observed in patients with 
ARVC was 3.7–10.6%, and was dependent on the study 
group and thus indirectly on the stage and genetic type 
of the underlying disease [36]. It is worth noting that in 
addition to the right ventricular function and morphology, 
a specific disease genotype is important during prognosis 
assessment. A multicentre study of 577 people with ARVC 
showed that the type of mutation and the number of muta-
tions were important in the assessed population because 
it was shown (surprisingly) that those who had ventricular 
fibrillation and sudden cardiac deaths were younger than 
those who were only diagnosed with sustained ventricular 
tachycardia (median age 23 vs. 36 years, p < 0.001) [34].
Supraventricular arrhythmias
There are only a few reports regarding the occurrence 
of supraventricular arrhythmias in the course of ARVC. 
A recent study by Camm et al. [37] showed that significant 
supraventricular arrhythmias (especially atrial fibrillation) 
in ARVC occur in approximately 14% of patients. Factors 
associated with the occurrence of supraventricular 
arrhythmias in patients with ARVC were: male sex, older 
age, and enlargement of the left atrium [37].
Autonomic system
In recent years, it has been observed that ARVC is also 
associated with adrenergic system dysfunction, which 
is manifested by a decrease in noradrenaline and cyclic 
adenosine-3’, 5’-monophosphatase in the myocardium. 
Decreased noradrenaline levels in the course of ARVC 
some times lead to abnormal stimulation of beta-adrener-
gic signalling pathways, and this can potentially result in 
increased myocardial fibrosis and increased arrhythmo-
genesis. Comparing endomyocardial biopsies of patients 
with ARVC to people with ventricular arrhythmia from the 
right ventricular outflow tract without structural heart 
disease, a significantly lower noradrenaline concentration 
was found in the ARVC group (p < 0.04), which indicates 
reduced activity of the sympathetic system in this group, 
and potential abnormalities in beta-adrenergic receptors 
function [38]. In another study, performed in patients 
with ARVC not taking antiarrhythmic drugs, significantly 
lower HRV values were observed, which reflected the 
sympathetic part of the cardiac autonomic system. A study 
by Paul et al. [39] also showed that 59% of patients with 
ARVC have sympathetic abnormalities independent of the 
genotype and degree of right ventricular dysfunction, and 
significantly increased risk of potentially life-threatening 
ventricular tachyarrhythmia (p < 0.0005). Studies using 
Holter’s assessment of autonomic system function have 
also confirmed the dysfunction of this system in patients 
with ARVC, and that the decrease in HRV parameters is 
associated not only with a more frequent occurrence of 
ventricular arrhythmias (p = 0.009), but also with a lower 
ejection fraction in both the right and the left ventricle [40].
Treatment
Numerous sudden cardiac arrest episodes in the course of 
ARVC have led to the implantation of cardioverter-defibrilla-
tors becoming the first-line therapy in this group of patients. 
In one of the ARVC registers, as many as 108 out of 137, 
patients were implanted with a cardioverter-defibrillator. 
Analysis of intracardiac ECGs in these patients confirmed 
that the vast majority of observed ventricular arrhythmias 
were monomorphic. As mentioned above, this study also 
showed that the only statistically significant predictor of 
life-threatening tachyarrhythmias (sustained ventricular 
tachycardia ≥ 240/min. or ventricular fibrillation) was 
younger age at the time of ARVC diagnosis (p = 0.036). It 
has also been shown that antitachycardia pacing were the 
most effective form of therapy in this group of patients (in 
92%), which indicates the importance of proper program-
ming [41].
462
Folia Cardiologica 2019, vol. 14, no. 5
www.journals.viamedica.pl/folia_cardiologica
Congenital heart disorders
Any congenital heart disease can result in cardiac arrhyth-
mias. In some cases, these arrhythmias can also be life-
-threatening. Among numerous congenital malformations 
with dominant right ventricular involvement and the 
frequent occurrence of cardiac arrhythmias, Ebstein’s ano-
maly and Fallot’s syndrome should be highlighted. Another 
disease, Eisenmenger syndrome (vascular lung disease) 
with the secondary development of irreversible pulmonary 
hypertension is the consequence of inadequately diagno-
sed and treated congenital defects with left-right leakage.
Ebstein’s anomaly
Ebstein’s anomaly is a rare disease, with an estimated 
frequency of about 5 per 100,000 live births. Although 
it is a congenital disease, it is often only diagnosed in 
adulthood. Ebstein’s anomaly consists of an embryonic 
defect causing the tricuspid valve leaflets to move deeper 
into the right ventricle, which is accompanied by atrialisa-
tion and possible leakage at the level of the atria. Typical 
for this disorder is the presence of additional right-sided 
AV conduction pathways, resulting in a significantly higher 
number of arrhythmia episodes than in the general popu-
lation. Atrioventricular recurrent tachycardia arising in the 
macro re-entry mechanism is sometimes poorly tolerated, 
manifesting in syncope in up to 30% of patients, and cases 
of its transition to ventricular fibrillation have been recorded 
[42]. In contrast, AFL or AF is most common in patients 
who are post-repair surgery (in 64% and 23% of patients, 
respectively) [43]. The incidence of AF increases with the 
age of the patient, resulting in up to a 100% increase in 
five-year mortality. On the other hand, sustained ventricu-
lar tachycardia relatively rarely appears spontaneously, 
although it can be induced during electrophysiological 
examination [42].
In one of the largest groups of patients with Ebstein’s 
anomaly from one centre (143 patients of the Mayo Clinic), 
it was shown that significant arrhythmias occurred in 31% 
of cases before operative correction of the defect. The most 
common were supraventricular tachycardia not associated 
with additional pathways (17%), and Wolff Parkinson White 
syndrome (with supraventricular tachyarrhythmias, 10%, 
and without, also 10%). Other arrhythmias in Ebstein’s 
anomaly, including atrial tachycardia, AFL as well as ventri-
cular tachycardia and ventricular fibrillation, were rare (1% 
each) [44]. There is no report available on the function of 
the autonomic system in patients with Ebstein’s anomaly 
and its impact on the development of cardiac arrhythmias.
Tetralogy of Fallot 
Another congenital heart disease that needs to be discus-
sed is tetralogy of Fallot, which involves the simultaneous 
occurrence of pulmonary stenosis, ventricular septal 
defect, overriding aorta, and secondary right ventricular 
hypertrophy. Tetralogy of Fallot occurs in up to 0.09% of 
live births. In previous studies, the risk of ventricular tachy-
cardia among people with tetralogy of Fallot was estimated 
at 4–14% in 20–30-year follow-ups [45]. Sudden cardiac 
deaths in the course of ventricular tachyarrhythmias have 
long been considered the most common cause of mortality 
in this disease. This view was not confirmed however in 
a meta-analysis involving 39 studies with a total popula-
tion of over 4,500 patients, where the risk of sudden death 
was determined to be 0.15% per year [46]. Interestingly, 
this risk does not increase linearly, but reaches its highest 
level 20–25 years after corrective surgery [47]. The in-
cidence of supraventricular arrhythmias among patients 
affected by this syndrome is also high, due to numerous 
lesions in the heart structures altered by the defect and 
repair surgery. Over many years of observation, episodes 
of supraventricular tachycardia in the reentry mechanism 
have been observed in up to 30% of patients. Patients 
with tetralogy of Fallot also often have episodes of AFL 
and AF [48]. It is well-documented that complex disorders 
of the structure and function of the heart in patients with 
tetralogy of Fallot cause irregularities in the functioning 
of the autonomic system. Several studies have shown 
that significantly lower values of HRV time and frequency 
analysis parameters are observed in adults with correc-
ted tetralogy of Fallot compared to healthy people. It is 
worth emphasising that these parameters improve along 
with the time elapsed since the procedure. Moreover, 
an inverse relationship has been found between the 
values of most HRV parameters and the duration of QRS 
complexes in ECG. This observation indicates that the 
greater the damage to the heart, the worse the function 
of the autonomic system, which may also translate into 
an increased risk of ventricular arrhythmias and sudden 
cardiac deaths in this group of patients [49].
Eisenmenger syndrome
Various types of cardiac arrhythmia are found in 15–20% 
of patients with vascular lung disease. In a study con-
ducted on a population of 167 people with Eisenmenger 
syndrome, with a mean age of 38 ± 9 years, significant 
tachyarrhythmias were found in 28 patients. This was most 
often supraventricular tachycardia, AF or AFL, and unstable 
and sustained ventricular tachycardia. Interestingly, only 
16% of the abovementioned study population received 
antiarrhythmic treatment. A trend towards an increased 
risk of death (p = 0.07) was observed among patients 
with known arrhythmia [50]. As in other patients with CPH, 
also the function of the autonomic heart system is dis-
turbed in patients with Eisenmenger syndrome. In a study 
assessing HRV parameters in this group, significantly 
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lower values were observed both in time and in frequency 
analysis (compared to the control group of healthy people, 
p = 0.001) [51].
Treatment
The treatment of cardiac arrhythmias in patients with 
congenital malformations does not differ significantly from 
standard therapy, but amiodarone is preferred for ventri-
cular tachyarrhythmias. However, invasive antiarrhythmic 
treatment should always be performed in an experienced 
centre. Despite the increased risk of arrhythmia in postope-
rative scar tissue, correction of the defect plays a key role 
in accordance with generally accepted standards.
Connective tissue diseases
Right ventricular involvement also occurs in the course of 
autoimmune connective tissue diseases. Cardiovascular 
involvement is most common in systemic sclerosis, lupus 
erythematosus, rheumatoid arthritis, polymyositis and der-
matomyositis, as well as mixed connective tissue disease. 
In none of these diseases does selective right ventricular 
involvement occur, but possible development of PH in 
their course is often the cause of various arrhythmias 
and autonomic dysfunction. The risk of arrhythmia in this 
group of patients also results from progressive fibrosis, 
including the conduction system and variously intensified 
inflammation [52, 53].
Patients with systemic sclerosis are at the highest 
risk of various cardiac arrhythmias, both tachy- and brady-
arrhythmia. The most common in people with this disease 
are numerous extrasystole beats, with a frequency of 
25–75% reported in Holter analyses. Moreover, it has 
been shown that the occurrence of numerous ventricular 
extrasystoles is associated with an increase in the inci-
dence of sudden cardiac deaths [52, 53]. Non-sustained 
supraventricular (approx. 50%) and ventricular tachycardia 
(in 7–13% of cases) are also very common in patients with 
systemic sclerosis. However, AF and AFL episodes are less 
frequent. In addition, AV conduction disorders, including 2nd 
and 3rd degree blocks, are also not uncommon in patients 
with systemic sclerosis [52, 53]. Analysis of HRV and HRT in 
patients with systemic sclerosis indicates a decrease in the 
activity of both components of the autonomic system of the 
heart, especially the parasympathetic part. An undoubted 
relationship between the deterioration of the autonomic 
cardiac system function and the development of PH in this 
group of patients has also been shown [54].
In the course of lupus erythematosus, the most frequ-
ently observed arrhythmia is inadequate sinus tachycardia. 
This occurs in up to 50% of patients and can be the only 
sign of heart involvement. Additionally, supraventricular 
extrasystoles are common, as well as short episodes of 
unstable supraventricular tachycardia (in approx. 30% of 
cases) and very rarely paroxysmal AF. However, ventricular 
arrhythmias and AV blocks in the population of people 
with systemic lupus erythematosus are uncommon. The 
reported frequency of additional ventricular beats is about 
8%, while in the case of non-sustained ventricular tachy-
cardia it is about 1% [53]. Among patients with systemic 
lupus erythematosus, as in people with systemic sclerosis, 
significantly lower HRV and HRT parameters have been 
observed, with a clear impairment of sympathetic heart 
tone, although parasympathetic tone is similar to that in 
healthy individuals [53].
In rheumatoid arthritis, in addition to other pro-
arrhythmic factors characteristic of connective tissue 
diseases, the presence of rheumatoid nodules in the 
myocardium, infiltration of the conductive system and de-
position of amyloid is typical. Cardiac involvement in this 
disease is usually asymptomatic, and arrhythmias appear 
relatively rarely [55].
Treatment
The therapy of arrhythmia and conductive disorders in 
people with connective tissue diseases does not differ 
significantly from the treatment appropriated for the 
general population. Knowledge of the underlying arrhyth-
mias, and proper treatment of the underlying disease, 
remain particularly important in this group of patients.
Conclusions
Diseases involving the right heart have a distinct patho-
physiology, clinical course, and potential complications. Ty-
pically, these diseases influence the function of autonomic 
nervous system, which leads to an increased potential for 
causing arrhythmias, with other types of arrhythmia being 
characteristic of particular disease entities (Table 1). It is 
important for clinicians to use this knowledge in practice, 
when treating patients with conditions listed in present 
study.
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Streszczenie
Prawa i lewa komora różnią się w swojej anatomii i funkcji, co ma swój wyraz w odmiennej budowie miokardium, zawar-
tości elementów układu bodźcoprzewodzącego oraz dystrybucji receptorów autonomicznego układu nerwowego. Wymie-
nione różnice sprawiają, że choroby przebiegające głównie z zajęciem prawych jam serca, takie jak: ostra zatorowość 
płucna, przewlekłe nadciśnienie płucne, zawał prawej komory serca czy arytmogenna kardiomiopatia prawokomorowa, 
a także wybrane wrodzone wady serca czy niektóre choroby układowe tkanki łącznej, odróżniają się na tle innych scho-
rzeń swoją patofizjologią, przebiegiem klinicznym oraz potencjalnymi komplikacjami. Prowadzi to również do zwiększo-
nej częstości wywoływania zaburzeń rytmu serca, przy czym dla poszczególnych jednostek charakterystyczne są inne 
rodzaje arytmii. W celu ułatwienia klinicystom wyboru metod diagnostycznych i leczniczych w poniższym opracowaniu 
zebrano aktualną wiedzę na temat zaburzeń rytmu oraz funkcji autonomicznego układu nerwowego serca w schorze-
niach przebiegających z zajęciem prawej komory.
Słowa kluczowe: zaburzenia rytmu serca, układ autonomiczny serca, ostra zatorowość płucna, nadciśnienie płucne, 
zajęcie prawej komory serca
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Table 1. Estimated incidence of various significant supraventricular and ventricular arrhythmias in various right ventricular involvement 
(data based on numerous references)
Arrhythmias Acute  
pulmonary  
embolism [%]
Chronic  
pulmonary 
hypertension 
[%]
Arrhythmogenic 
right ventricular 
cardiomyopathy 
[%]
Ebstein’s  
anomaly [%]
Tetralogy 
of Fallot 
[%]
Eisenmenger 
syndrome [%]
Systemic 
sclerosis [%]
AF 13 5.6  
 
 
14**
No data (prior to  
correction) 
23 (post correction)
No data 21 No data
AFL No data 6.3 1 (64) No data < 7 No data
SVT < 24–39* > 1.3 17 (no data) 30 29 50
nsVT No data 13.6–27.3
3.7–10.6
< 1 (no data)
4–14
21 7–13.5
sVT No data No data 1 (no data) 21 No data
*Including supraventricular tachycardia (SVT) with atrial fibrillation (AF) and atrial flutter (AFL); **mostly AF; nsVT — non-sustained ventricular tachycardia; sVT — sustained ventricular tachycardia; no data — 
no data available
} }
}
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